Literature DB >> 30666557

CRISPR/Cas9 for overcoming drug resistance in solid tumors.

Ali Saber1, Bin Liu1, Pirooz Ebrahimi2,3, Hidde J Haisma4.   

Abstract

OBJECTIVES: In this review, we focus on the application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated nuclease 9 (Cas9), as a powerful genome editing system, in the identification of resistance mechanisms and in overcoming drug resistance in the most frequent solid tumors. DATA ACQUISITION: Data were collected by conducting systematic searching of scientific English literature using specific keywords such as "cancer", "CRISPR" and related combinations.
RESULTS: The review findings revealed the importance of CRISPR/Cas9 system in understanding drug resistance mechanisms and identification of resistance-related genes such as PBRM1, SLFN11 and ATPE1 in different cancers. We also provided an overview of genes, including RSF1, CDK5, and SGOL1, whose disruption can synergize with the currently available drugs such as paclitaxel and sorafenib.
CONCLUSION: The data suggest CRISPR/Cas9 system as a useful tool in elucidating the molecular basis of drug resistance and improving clinical outcomes. Graphical abstract The mechanisms of CRISPR/Cas9-mediated genome editing and double-strand breaks (DSBs) repair.

Entities:  

Keywords:  CRISPR/Cas9; Clinical outcome; Drug resistance; Drug response; Solid tumor; Targeted therapy

Mesh:

Substances:

Year:  2019        PMID: 30666557      PMCID: PMC7214581          DOI: 10.1007/s40199-019-00240-z

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   3.117


  72 in total

1.  Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient.

Authors:  P Ferronika; H van den Bos; A Taudt; D C J Spierings; A Saber; T J N Hiltermann; K Kok; D Porubsky; A J van der Wekken; W Timens; F Foijer; M Colomé-Tatché; H J M Groen; P M Lansdorp; A van den Berg
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

2.  Rsf-1 Influences the Sensitivity of Non-Small Cell Lung Cancer to Paclitaxel by Regulating NF-κB Pathway and Its Downstream Proteins.

Authors:  Xitao Chen; Xiaodi Sun; Jingqian Guan; Junda Gai; Jilin Xing; Lin Fu; Shuli Liu; Feifei Shen; Keyan Chen; Wenya Li; Libo Han; Qingchang Li
Journal:  Cell Physiol Biochem       Date:  2017-12-15

3.  Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells.

Authors:  Min Zhou; Xinjian Liu; Zonghai Li; Qian Huang; Fang Li; Chuan-Yuan Li
Journal:  Int J Cancer       Date:  2018-03-30       Impact factor: 7.396

4.  The E3 Ligase CHIP Mediates p21 Degradation to Maintain Radioresistance.

Authors:  Kuntal Biswas; Sukumar Sarkar; Kangping Du; David L Brautigan; Tarek Abbas; James M Larner
Journal:  Mol Cancer Res       Date:  2017-02-23       Impact factor: 5.852

Review 5.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

6.  Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1.

Authors:  Alok Ranjan; Sanjay K Srivastava
Journal:  Oncotarget       Date:  2017-05-16

7.  MUC16 overexpression induced by gene mutations promotes lung cancer cell growth and invasion.

Authors:  Madiha Kanwal; Xiao-Jie Ding; Xin Song; Guang-Biao Zhou; Yi Cao
Journal:  Oncotarget       Date:  2018-01-12

8.  Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.

Authors:  Alvaro Avivar-Valderas; Robert McEwen; Amir Taheri-Ghahfarokhi; Larissa S Carnevalli; Elizabeth L Hardaker; Marcello Maresca; Kevin Hudson; Elizabeth A Harrington; Francisco Cruzalegui
Journal:  Oncotarget       Date:  2018-04-20

Review 9.  The Different Mechanisms of Cancer Drug Resistance: A Brief Review.

Authors:  Behzad Mansoori; Ali Mohammadi; Sadaf Davudian; Solmaz Shirjang; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2017-09-25

10.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

Authors:  Elza C de Bruin; Nicholas McGranahan; Richard Mitter; Max Salm; David C Wedge; Lucy Yates; Mariam Jamal-Hanjani; Seema Shafi; Nirupa Murugaesu; Andrew J Rowan; Eva Grönroos; Madiha A Muhammad; Stuart Horswell; Marco Gerlinger; Ignacio Varela; David Jones; John Marshall; Thierry Voet; Peter Van Loo; Doris M Rassl; Robert C Rintoul; Sam M Janes; Siow-Ming Lee; Martin Forster; Tanya Ahmad; David Lawrence; Mary Falzon; Arrigo Capitanio; Timothy T Harkins; Clarence C Lee; Warren Tom; Enock Teefe; Shann-Ching Chen; Sharmin Begum; Adam Rabinowitz; Benjamin Phillimore; Bradley Spencer-Dene; Gordon Stamp; Zoltan Szallasi; Nik Matthews; Aengus Stewart; Peter Campbell; Charles Swanton
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

View more
  7 in total

Review 1.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

2.  CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.

Authors:  Jiang Chen; Shi Jiang; Huijiang Shao; Bixia Li; Tong Ji; Daniel Staiculescu; Jiayan He; Jie Zhao; Liuxin Cai; Xiao Liang; Junjie Xu; Xiujun Cai
Journal:  Sci China Life Sci       Date:  2022-04-01       Impact factor: 10.372

Review 3.  CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues.

Authors:  Roberto Piergentili; Alessandro Del Rio; Fabrizio Signore; Federica Umani Ronchi; Enrico Marinelli; Simona Zaami
Journal:  Cells       Date:  2021-04-21       Impact factor: 7.666

Review 4.  5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent.

Authors:  Soudeh Ghafouri-Fard; Atefe Abak; Farhad Tondro Anamag; Hamed Shoorei; Faranak Fattahi; Seyed Alireza Javadinia; Abbas Basiri; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-19       Impact factor: 6.244

Review 5.  Targeting Cancer with CRISPR/Cas9-Based Therapy.

Authors:  Katarzyna Balon; Adam Sheriff; Joanna Jacków; Łukasz Łaczmański
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

Review 6.  Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy.

Authors:  María Cecilia Sanmartin; Francisco Raúl Borzone; María Belén Giorello; Gustavo Yannarelli; Norma Alejandra Chasseing
Journal:  Front Bioeng Biotechnol       Date:  2022-04-14

7.  CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation.

Authors:  Bin Liu; Olivia Adaly Diaz Arguello; Deng Chen; Siwei Chen; Ali Saber; Hidde J Haisma
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.